Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Obesity Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

    For all other requests, please visit our Contact Lilly services.

    Foundayo™ (orforglipron)

    Full Prescribing Information

    Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
    Published Date: April 17, 2026
    Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
    Published Date: September 2, 2025
    Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-Peptide GLP-1 Receptor Agonist
    Published Date: February 24, 2024
    Orforglipron (LY3502970), A Novel, Oral Non-Peptide Glucagon-Like Peptide-1 Receptor Agonist: A Phase 1a, Blinded, Placebo-Controlled, Randomized, Single- and Multiple-Ascending-Dose Study in Healthy Participants
    Published Date: June 21, 2023

    Treatment with Orforglipron, an Oral Glucagon Like Peptide-1 Receptor Agonist, is Associated with Improvements of CV Risk Biomarkers in Patients with Type 2 Diabetes or Obesity Without Diabetes
    Published Date: June 6, 2025
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
    Published Date: June 23, 2023

    Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial.
    Published Date: May 13, 2026
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for the Treatment of Obesity in People with Type 2 Diabetes (ATTAIN-2): A Phase 3, Double-Blind, Randomised, Multicentre, Placebo-Controlled Trial.
    Published Date: December 20, 2025
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
    Published Date: September 16, 2025

    No Publication Journals

    Zepbound® (tirzepatide)

    Full Prescribing Information

    Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
    Published Date: June 24, 2025
    Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes
    Published Date: March 01, 2023
    Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Published Date: June 08, 2022

    Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
    Published Date: June 25, 2025
    Extent of MASH resolution without worsening of fibrosis across clinically relevant subgroups in the SYNERGY-NASH phase 2 trial
    Published Date: June 6, 2025
    Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    Published Date: June 08, 2024
    Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
    Published Date: May 20, 2024

    Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
    Published Date: November 04, 2025
    A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.
    Published Date: June 25, 2025
    Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
    Published Date: June 24, 2025
    Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
    Published Date: June 10, 2025
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
    Published Date: May 11, 2025
    Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
    Published Date: May 6, 2025
    Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
    Published Date: March 31, 2025
    Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
    Published Date: March 12, 2025
    Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
    Published Date: February 28, 2025
    Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
    Published Date: February 25, 2025
    Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
    Published Date: January 12, 2025
    Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-related Heart Failure with Preserved Ejection Fraction: The SUMMIT CMR Substudy
    Published Date: November 20, 2024
    Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity
    Published Date: November 18, 2024
    Effects of Tirzepatide on Circulatory Overload and End-Organ Damage in Heart Failure With Preserved Ejection Fraction and Obesity: a secondary analysis of the SUMMIT trial
    Published Date: November 17, 2024
    Tirzepatide for Heart Failure With Preserved Ejection Fraction and Obesity
    Published Date: November 15, 2024
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    Published Date: November 13, 2024
    Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.
    Published Date: November 12, 2024
    Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.
    Published Date: September 16, 2024
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    Published Date: June 21, 2024
    Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
    Published Date: May 31, 2024
    Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes
    Published Date: March 29, 2024
    Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial.
    Published Date: March 26, 2024
    Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index >/=27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
    Published Date: February 05, 2024
    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
    Published Date: December 11, 2023
    Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with overweight and obesity: SURMOUNT-1 post-hoc analysis
    Published Date: November 6, 2023
    Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
    Published Date: October 15, 2023
    Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial
    Published Date: September 14, 2023
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Published Date: June 26, 2023
    Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program.
    Published Date: December 7, 2022
    Tirzepatide Once Weekly for the Treatment of Obesity
    Published Date: June 9, 2022

    Attitudinal Factors Influencing Willingness to Use Anti-Obesity Medication in Adults with Obesity
    Published Date: September 9, 2025
    Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial
    Published Date: June 12, 2025
    Perspectives on Obesity Management and the Use of Anti-Obesity Medicine from US Employees and Employers: Results from the OBSERVE Study.
    Published Date: April 2, 2025
    Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.
    Published Date: March 7, 2025
    Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
    Published Date: February 25, 2025
    Understanding the Impact of Non-alcoholic Steatohepatitis with Metabolic Comorbidities on Adults: A Real-World Qualitative Study
    Published Date: February 29, 2024
    EXIST: EXamining rIsk of excesS adiposiTy-Machine learning to predict obesity-related complications
    Published Date: August 23, 2023
    Real-world primary nonadherence to antiobesity medications.
    Published Date: August 23, 2023
    Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data
    Published Date: May 31, 2023
    Five-Year Morbidity and Mortality Rates in a U.S. Population with Obesity with and without Prediabetes
    Published Date: May 3, 2023
    The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes.
    Published Date: February 23, 2023
    Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review.
    Published Date: March 11, 2022
    Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
    Published Date: August 24, 2021
    Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015-2018.
    Published Date: July 12, 2021

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.93 05/2026 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2026. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly